Journal Article

Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis

Jon Jin Kim, Simon C. Waller and Christopher J. Reid

in Clinical Kidney Journal

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 5, issue 1, pages 34-36
Published in print February 2012 | ISSN: 1753-0784
Published online January 2012 | e-ISSN: 1753-0792 | DOI: https://dx.doi.org/10.1093/ckj/sfr174
Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis

Show Summary Details

Preview

Disorders in complement regulation are a major cause of atypical haemolytic–uraemic syndrome (aHUS). Eculizumab, a monoclonal antibody targeting complement C5 and blocking the terminal complement cascade, should theoretically be useful in this disease, particularly when associated with specific complement pathway anomalies such as Factor H deficiency. Eculizumab is emerging as an effective treatment for post-transplant aHUS recurrence and may have a role in treating de novo aHUS, halting the haemolytic process. In this case report, we describe the fourth case of aHUS treated with eculizumab. In our patient, with a known complement Factor H mutation, not only has the disease process become quiescent but also this therapy has led to significantly improved renal function so that dialysis is no longer necessary.

Keywords: atypical haemolytic–uraemic syndrome; dialysis; eculizumab; plasma exchange

Journal Article.  1259 words.  Illustrated.

Subjects: Medicine and Health

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.